Medical Facilities (DR) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
23 Nov, 2025Executive summary
Second quarter results were impacted by headwinds at Sioux Falls Specialty Hospital (SFSH), mainly due to the relocation of its primary physician group's clinic, which reduced complex surgical case volume and affected case and payer mix.
Facility service revenue declined 1.3% to $80.6 million; excluding SFSH, revenue increased 6.5%.
Surgical case volumes fell 0.9%; excluding SFSH, volumes were up 0.1%.
Income from operations dropped 5% to just under $12 million; excluding SFSH, it rose 98.9%.
EBITDA was $16 million, down 4.7% year-over-year.
Financial highlights
Net income from continuing operations rose 375.1% year-over-year to $9.6 million for Q2 2025.
Basic EPS was $0.24, up from $(0.11) in Q2 2024.
Operating expenses before non-cash share-based compensation were $68.5 million, up 0.3% year-over-year.
Distributable cash flow for Q2 was C$5.3 million, down 43.3% year-over-year.
Quarterly cash dividend of C$0.09 per share, annualized yield of 2.28%.
Outlook and guidance
Operations at SFSH are expected to normalize in the second half of the year, with the major impact from the clinic relocation now largely behind.
Other hospitals are expected to maintain strong performance due to higher volumes and favorable payor mix.
Recruitment at Arkansas Surgical Hospital is progressing, with a new pain doctor starting and a new spine surgeon joining in September 2025.
Latest events from Medical Facilities
- Strong revenue and earnings growth, major asset sales, and buybacks boosted shareholder returns.DR
Q4 202512 Mar 2026 - Revenue and EBITDA rose on strong case volumes; PPP loan forgiveness to boost Q3.DR
Q2 20242 Feb 2026 - Q3 net income up 263% and revenue up 11.2%, driven by PPP loan forgiveness and case growth.DR
Q3 202416 Jan 2026 - Net income nearly doubled in 2024, fueled by asset sales and robust capital returns.DR
Q4 202426 Dec 2025 - Revenue and EBITDA stable, net income up, and $44.3M returned to shareholders via buybacks.DR
Q1 202525 Nov 2025 - 7.5% revenue growth, 10.2% higher EBITDA, and $5.6M in share buybacks in Q3 2025.DR
Q3 202513 Nov 2025